Sfoglia per AUTORE
PISANO C
Collezione ASL Torino 4
Items : 7
Role of radium-223 discontinuation due to adverse events in castration-resistant prostate cancer patients. A retrospective monocentric analysis. in Tumori / Tumori. 2023 Apr;109(2):233-243. doi: 10.1177/03008916221077144. Epub 2022 Mar 31.
2023
ASL Asti
ASL Torino 4
AO Ordine Mauriziano
AOU San Luigi di Orbassano
Buttigliero C; Di Maio M; Scagliotti GV; Ungaro A; Parlagreco E; Audisio A; Audisio M; Angusti T; Parente A; Di Stefano RF; Urban S; Pisano C; Samuelly A; Tucci M; Turco F;
Management of Oligoprogression in Patients with Metastatic NSCLC Harboring ALK Rearrangements. in Cancers / Cancers (Basel). 2022 Jan 30;14(3):718. doi: 10.3390/cancers14030718.
2022
ASL Torino 4
AOU San Luigi di Orbassano
Reale ML; Novello S; Jacobs F; De Filippis M; Pisano C;
Antibody-Drug Conjugates in Urothelial Carcinoma: A New Therapeutic Opportunity Moves from Bench to Bedside. in Cells / Cells. 2022 Feb 25;11(5):803. doi: 10.3390/cells11050803.
2022
ASL Asti
ASL Torino 4
AO Ordine Mauriziano
AOU San Luigi di Orbassano
Delcuratolo MD; Ungaro A; Buttigliero C; Di Maio M; Audisio A; Di Prima L; Turco F; Scagliotti GV; Pisano C; Tucci M;
How far we have come targeting BRAF-mutant non-small cell lung cancer (NSCLC). in Cancer treatment reviews / Cancer Treat Rev. 2022 Feb;103:102335. doi: 10.1016/j.ctrv.2021.102335. Epub 2021 Dec 31.
2022
ASL Torino 4
AOU San Luigi di Orbassano
Novello S; Ambrogio C; Swalduz A; Santamaria D; Pradines A; Planchard D; Nadal E; Mazieres J; Mezquita L; Pisano C; Tabbò F; Ortiz-Cuaran S;
Prognostic factors in metastatic castration resistant prostate cancer patients treated with radium-223: a retrospective study. in Minerva urology and nephrology / Minerva Urol Nephrol. 2022 Dec;74(6):703-713. doi: 10.23736/S2724-6051.22.04701-2. Epub 2022 Feb 11.
2022
ASL Asti
ASL Torino 4
AO Ordine Mauriziano
AOU San Luigi di Orbassano
Pisano C; DI Maio M; Tucci M; Scagliotti GV; Samuelly A; DI Stefano RF; Turco F; Bungaro M; Parente A; Buttigliero C; Angusti T;
Treatment intensification for metastatic prostate cancer: New treatment landscapes in androgen deprivation-based therapy. in Cancer communications (London, England) / Cancer Commun (Lond). 2022 Aug;42(8):683-688. doi: 10.1002/cac2.12340. Epub 2022 Jul 22.
2022
ASL Asti
ASL Cuneo 2
ASL Torino 4
ASL Cuneo 1
AO Ordine Mauriziano
AOU San Luigi di Orbassano
Turco F; Ungaro A; Audisio M; Scagliotti GV; Di Maio M; Delcuratolo MD; Audisio A; Ortega C; Pisano C; Buttigliero C; Di Stefano RF; Tucci M;
Prognostic role of platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio in patients with metastatic castration resistant prostate cancer treated with abiraterone or enzalutamide. in Minerva urology and nephrology / Minerva Urol Nephrol. 2021 Dec;73(6):803-814. doi: 10.23736/S2724-6051.21.04186-2. Epub 2021 Mar 29.
2021
ASL Asti
AOU San Luigi di Orbassano
ASL Vercelli
ASL Torino 4
AO Ordine Mauriziano
Buttigliero C; DI Maio M; Scagliotti GV; Tarenghi F; Vignani F; Bungaro M; Samuelly A; Turco F; DI Stefano RF; Tucci M; Pisano C;